Maro Publications

Transdermal Drug Release

Notes

*6/25/2012

Maro Topics

Comments

Patents with Abstracts

Controlled Drug Release

Microneedles

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 

Notes

Transdermal is a route of administration wherein active ingredients are delivered across the skin for systemic distribution. Examples include transdermal patches used for medicine delivery, and transdermal implants used for medical or aesthetic purposes.

Although the skin is a large and logical target for drug delivery, its basic functions limit its utility for this purpose. The skin functions mainly to protect the body from external insults (e.g. harmful substances and microorganisms) and to contain all body fluids. It must be tough, yet flexible enough to allow for movement. The lipids in our skin serve as poor conductors of electricity and can hence protect us from electrical currents if the need so arises.

There are two important layers to the human skin: (1) the Epidermis and (2) the Dermis. For transdermal delivery, drugs must pass through the two sublayers of the epidermis to reach the microcirculation of the dermis.

The Stratum corneum is the top layer of the skin and varies in thickness from approximately ten to several hundred micrometres, depending on the region of the body.  It is composed of layers of dead, flattened keratinocytes surrounded by a lipid matrix, which together act as a brick-and-mortar system that is difficult to penetrate.

The stratum corneum provides the most significant barrier to diffusion. In fact, the stratum corneum is the barrier to approximately 90% of transdermal drug applications. However, nearly all molecules penetrate it to some minimal degree.   Below the stratum corneum lies the viable epidermis. This layer is about ten times as thick as the stratum corneum; however, diffusion is much faster here due to the greater degree of hydration in the living cells of the viable epidermis. Below the epidermis lies the dermis, which is approximately one millimeter thick, 100 times the thickness of the stratum corneum.  The dermis contains small vessels that distribute drugs into the systemic circulation and to regulate temperature, a system known as the skin's microcirculation.

“There are two main pathways by which drugs can cross the skin and reach the systemic circulation. The more direct route is known as the transcellular pathway. By this route, drugs cross the skin by directly passing through both the phospholipids membranes and the cytoplasm of the dead keratinocytes that constitute the stratum corneum.

Although this is the path of shortest distance, the drugs encounter significant resistance to permeation. This is because the drugs must cross the lipophilic membrane of each cell, then the hydrophilic cellular contents containing keratin, and then the phospholipid bilayer of the cell one more time. This series of steps is repeated numerous times to traverse the full thickness of the stratum corneum.

The other more common pathway through the skin is via the intercellular route. Drugs crossing the skin by this route must pass through the small spaces between the cells of the skin, making the route more tortuous. Although the thickness of the stratum corneum is only about 20 µm, the actual diffusional path of most molecules crossing the skin is on the order of 400 µm.[4] The 20-fold increase in the actual path of permeating molecules greatly reduces the rate of drug penetration.

 A third pathway to breach the Stratum Corneum layer is via tiny microchannels created by a medical micro-needling device of which there are many brands and variants. The original microneedling device is the Dermaroller®.  It was patented in Germany in 2000. Other devices such as that invented by Dr Fernandes called the CIT-Roller followed the Dermaroller®.  The latest generation of microneedle roller as invented and patented by Medik8, a British biotechnology company, reduces pain associated with treatment by the use of sterile small diameter titanium needles. Investigations at the University of Marburg, Germany, using a standard Franz diffusion cell showed that this approach is efficient in enhancing skin penetration ability for lipophilic as well as hydrophilic compounds.  The micro-needling approach is also seen as 'the vaccine of the future'.”

(Wikipedia, Transdermal Drug Delivery, 6/25/2012)

 --------------------------------------------------------

“Transdermal drug delivery is an important route for pharmaceutical actives, but the outer layer of skin, the 10-20 micrometer thick layer called the stratum corneum, is an effective barrier for many chemical entities. Hence, the number of pharmaceutically active materials that can penetrate into the body through the skin is very limited, and is defined by factors such as polarity, log P, and molecular size. At the same time, many drugs are being synthesized which are unsuitable for oral delivery (for example, due to instability in the gastrointestinal tract, or first pass liver metabolism). Hence, the skin is an attractive, if problematic, route for delivery of these drugs, as well as drugs that act in the skin, but perhaps have systemic side effects.

Several methods have been developed in order to compromise the skin barrier function to allow penetration of drugs into, and analytes out of (for monitoring purposes), the body. These include sonophoresis, iontophoresis and microneedles. U.S. Pat. No. 3,964,482 describes the use of microneedles to assist in the delivery of drugs across the skin. Microneedles puncture the stratum corneum, allowing passage of drug into the subject, but preferably do not induce a pain response because the microneedles do not penetrate to the dermal layer of the skin which is provided with nerve cells.”

[Kirby, US Patent 8,192,787 (6/5/2012)]

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

Interested!!
Bookmark this page to follow future developments!.
(RDC 6/5/2012)

 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

Roger D. Corneliussen
Editor
www.maropolymeronline.com

Maro Polymer Links
Tel: 610 363 9920
Fax: 610 363 9921
E-Mail: cornelrd@bee.net  

***********************************

Copyright 2012 by Roger D. Corneliussen.
No part of this transmission is to be duplicated in any manner or forwarded by electronic mail without the express written permission of Roger D. Corneliussen
**************************************

* Date of latest addition; date of first entry is 6/25/2012.